Greenwich Therapeutics (NASDAQ:GLSI) Stock Price Analysis

GP2 was sold to Liberty Interactive in 2008 and became a free-to-play racing game in 2010. Last year, the rights to commercialize F2 were licensed from the FIA, and F2 brought in $15.2 million in revenue. GP3 was announced in 2008 but has not yet been launched. Liberty does not have to share basic information regarding the company’s business, but it’s not a good sign for investors.

Greenwich Therapeutics (NASDAQ: GLSI) Stock Price Analysis

Greenwich Therapeutics (NASDAQ: GLSI) went public in September 2020. The company raised $6.2 million by offering 1.26 million shares of common stock to the public. Shares of GLSI have been trading at or below their IPO price for more than ten weeks. The company’s shares went public only after the company announced a poster presentation at the San Antonio Breast Cancer Symposium, where it revealed a 0% recurrence rate for women with breast cancer.

GP2 is an immunotherapy designed to prevent the recurrence of breast cancer

The GP2 Phase IIb trial presented final results from the five-year safety assessment of GP2 immunotherapy for metastatic breast cancer. In general, the immunotherapy was well tolerated, with no serious adverse events reported. GLSI Stock Although these results are encouraging, further research is necessary to confirm the effectiveness of this immunotherapy. For now, the GP2 trial has not yet been approved for wider use.

GP2 is an immunotherapy designed to treat patients with HER2-positive breast cancer. It works by blocking the growth factor of ER-positive cells that cause cancer to grow. The treatment has a high success rate. Patients have been able to avoid recurrence in more than 90% of cases. The GP2+GM-CSF combination has demonstrated high recurrence-free rates and a low risk of recurrence.

In a phase Ib trial of the GP2 vaccine, the vaccine was shown to prevent the recurrence of BC in 94% of patients with high HER2 expression. Furthermore, the immunotherapy was well tolerated, with a toxicity profile similar to that of GM-CSF alone. It also showed that the vaccine was well tolerated by patients, as most side effects were resolved with acetaminophen.

GP2 is the company’s only asset

GP2 is Greenwich Therapeutics’ sole pipeline candidate. The company’s stock would have suffered a big blow if this clinical trial failed to show any progress, but positive data from the phase 2b study provided investors with a sigh of relief. This broad immune response could increase the chances that GP2 will work well when combined with Herceptin-based products. Investors may be willing to wait for more positive clinical data before making a decision.

GP2 is an immunoadjuvant that targets HER2/neu, which is a type of cancer cell expressed by more than 70% of breast tumors. This gene is expressed on nearly half of all breast tumors, and amplification of the gene is associated with a worse outcome for patients. In addition to breast cancer, GP2 is active against a wide variety of other tumor types.

GP2 was sold to Liberty Interactive in 2008 and became a free-to-play racing game in 2010. Last year, the rights to commercialize F2 were licensed from the FIA, and F2 brought in $15.2 million in revenue. GP3 was announced in 2008 but has not yet been launched. Liberty does not have to share basic information regarding the company’s business, but it’s not a good sign for investors.

1 thought on “Greenwich Therapeutics (NASDAQ:GLSI) Stock Price Analysis”

Comments are closed.